Meta-analysis of randomized controlled trials examining the safety and efficacy of bempedoic acid

Abstract Funding Acknowledgements Type of funding sources: None. Introduction Bempedoic acid (BA), an inhibitor ATP citrate lyase, has emerged as a new therapy for patients with dyslipidemia. The objective this study was to perform meta-analysis BA's safety and cholesterol lowering efficacy. Methods A performed using RCTs testing the efficacy BA versus placebo. primary analysis calculated odds ratio (OR) 95% confidence interval (CI) any adverse events, muscular-related AEs including myopathy, muscle weakness, myalgias, well serious self-defined by individual RCT. Additionally, we evaluated mean difference (MD) CI low density lipoprotein-cholesterol (LDL-C), non-high (non-HDL-C), total (TC), apolipoprotein B (ApoB) at 12 weeks, LDL-C 24 weeks use compared Results Four were identified comparing There no increased risk AE [OR 1.04; 95%CI 0.89, 1.22], 1.07; 0.87, 1.34], or 1.25; 0.98, 1.58] resulted in significant reduction [MD -21.06; -24.49, -17.62], TC -16.02; -19.09, -12.93], non-HDL-C -17.84; -21.34, -14.34], ApoB -14.19; -17.18, -11.21] -16.42; -18.15, -14.69] Conclusion In placebo, significantly reduced levels LDL-C, TC, non-HDL-C, not associated AE, AE. Further studies longer time follow up are needed confirm long term effects BA.